OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Race to control tough ovarian cancer: Three-Way drug showdown
Disease control OngoingThis study is testing which combination of three drugs works best to control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. It involves 444 patients and compares a standard two-drug combo agains…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for recurrent ovarian cancer? early trial tests drug to boost chemo
Disease control OngoingThis early-stage study is testing whether adding an experimental drug called berzosertib (M6620) to standard chemotherapy (carboplatin and gemcitabine) is safe and might work better for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned. The main goal …
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Two-Pill attack on tough ovarian cancers
Disease control OngoingThis study is testing a combination of two oral drugs, olaparib and cediranib, to see if they can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is for women whose cancer has returned after previous treatment. The main goals are to see if the dru…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC
-
Scientists test Immune-Boosting combo to fight returning ovarian cancer
Disease control OngoingThis study is testing if a two-drug combination works better than a single drug to control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. It compares a targeted pill (olaparib) alone to the pill plus an immunotherapy drug (tr…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New targeted attack on tough ovarian cancer tested against standard care
Disease control OngoingThis study is for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It compares a new two-drug combination (bevacizumab + anetumab ravtansine) against a standard two-drug combination (bevacizumab + paclit…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Two-Pronged attack on tough cancers shows promise
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control th…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Scientists test new drug to weaken ovarian cancer before surgery
Knowledge-focused OngoingThis early study is testing if a drug called adavosertib, given before surgery, can affect the DNA of tumors in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goal is to learn how the drug changes the cancer cells at a molecular level, whic…
Matched conditions: OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC